Search
A new laboratory study provides evidence about how advanced age can be protective against cancer — with implications for treating patients in different age groups.
A study of nearly 900 kidney cancer tumors has identified previously unknown biomarkers that correlate with better treatment responses to immunotherapy and targeted therapy.
On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to zenocutuzumab (Bizengri®), the first approved systemic therapy for patients with advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) fusion and pancreatic adenocarcinoma harboring a (NRG1) fusion.
As we approach the end of 2019, learn about some of the biggest advances in clinical research made this year at MSK.
Fourteen young scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 14, 2025, as part of Memorial Sloan Kettering’s 46th annual academic convocation.
Degrees were presented and awards were given at the 35th annual ceremony held on May 14.
Memorial Sloan Kettering Cancer Center (MSK) issued the following statement today regarding financial results for the six months ended June 30, 2023.
MSK researchers have identified two signaling pathways that work together to spur the spread of lung cancer. Taking away one of those signals could help slow or stop metastasis, findings in animal models suggest.
Several Memorial Sloan Kettering Cancer Center (MSK) physician-scientists have been recognized by the American Society of Clinical Oncology (ASCO).
Chemotherapy is a common treatment for acute myeloid leukemia, but patients often stop responding. Until now, not much was known about why.